Cartesian Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RNAC Nasdaq 8731 https://www.cartesiantherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cartesian Therapeutics Inc

Cartesian Therapeutics Announces New Employment Inducement Grants - Oct 4th, 2024 11:05 am
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis - Sep 9th, 2024 11:00 am
Cartesian Therapeutics Announces New Employment Inducement Grant - Sep 6th, 2024 11:05 am
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - Sep 3rd, 2024 11:00 am
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Aug 26th, 2024 11:00 am
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 8th, 2024 11:00 am
Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs - Jul 2nd, 2024 8:08 pm
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik - Jul 2nd, 2024 8:05 pm
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus - Jul 2nd, 2024 10:31 am
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing - Jul 2nd, 2024 10:31 am
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis - Jul 2nd, 2024 10:30 am
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis - May 22nd, 2024 11:00 am
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - May 13th, 2024 8:30 pm
Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... - May 10th, 2024 7:12 pm
Cartesian Therapeutics Reports First Quarter 2024 Earnings - May 9th, 2024 10:57 am
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 8th, 2024 11:00 am
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting - Apr 22nd, 2024 8:30 pm
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference - Apr 4th, 2024 11:30 am
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split - Mar 28th, 2024 8:05 pm
Cartesian Therapeutics Director Acquires 3.2% More Stock - Mar 21st, 2024 10:49 am